Home > Publications Database > Manifestationen im Zentralnervensystem nach COVID-19. > print

001     164021
005     20240313115344.0
024 7 _ |a 10.1007/s00115-022-01294-2
|2 doi
024 7 _ |a pmid:35552466
|2 pmid
024 7 _ |a pmc:PMC9096778
|2 pmc
024 7 _ |a 0028-2804
|2 ISSN
024 7 _ |a 1433-0407
|2 ISSN
024 7 _ |a altmetric:128238791
|2 altmetric
037 _ _ |a DZNE-2022-00684
041 _ _ |a German
082 _ _ |a 610
100 1 _ |a Gerhard, Ameli
|b 0
245 _ _ |a Manifestationen im Zentralnervensystem nach COVID-19.
260 _ _ |a Heidelberg
|c 2022
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1661509180_607
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY: https://creativecommons.org/licenses/by/4.0/
520 _ _ |a Numerous diseases of the central nervous system (CNS), especially in the postacute phase after an infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been described. These include neuroimmunologically mediated diseases, such as encephalopathy, encephalitis, myelitis, acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis (ANHLE) and neuromyelitis optica spectrum disorder (NMOSD) as well as others, such as posterior reversible encephalopathy syndrome (PRES), opsoclonus myoclonus ataxia (OMA) and cerebrovascular diseases. A parainfectious or postinfectious association is discussed but the pathophysiological mechanisms are so far unknown. Underlying mechanisms could be a virus-triggered overactivation of the immune system with hyperinflammation and cytokine storm but possibly also the development of specific autoantibodies against CNS tissue. Direct damage due to the invasion of SARS-CoV‑2 into the brain or spinal cord does not seem to play a relevant role. An exact clinical phenotyping and initiation of additional diagnostics are recommended, also to rule out other causes. To date no medicinal treatment options for CNS manifestations of long COVID exist; however, first results regarding inflammation and autoimmunity are promising and could lead to new treatment approaches.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Autoantibodies
|2 Other
650 _ 7 |a Encephalitis
|2 Other
650 _ 7 |a Hyperinflammation
|2 Other
650 _ 7 |a Immunotherapy
|2 Other
650 _ 7 |a Myelitis
|2 Other
650 _ 2 |a COVID-19: complications
|2 MeSH
650 _ 2 |a Central Nervous System
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Nervous System Diseases: etiology
|2 MeSH
650 _ 2 |a Posterior Leukoencephalopathy Syndrome
|2 MeSH
650 _ 2 |a SARS-CoV-2
|2 MeSH
650 _ 2 |a Post-Acute COVID-19 Syndrome
|2 MeSH
700 1 _ |a Prüß, Harald
|0 P:(DE-2719)2810931
|b 1
|u dzne
700 1 _ |a Franke, Christiana
|0 P:(DE-2719)2811159
|b 2
|u dzne
773 _ _ |a 10.1007/s00115-022-01294-2
|0 PERI:(DE-600)1462945-8
|n 8
|p 769-778
|t Der Nervenarzt
|v 93
|y 2022
|x 0028-2804
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/164021/files/DZNE-2022-00684.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/164021/files/DZNE-2022-00684.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:164021
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810931
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 2
|6 P:(DE-2719)2811159
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-12
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NERVENARZT : 2021
|d 2022-11-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-01-28
|w ger
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-12
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-12
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-12
920 1 _ |0 I:(DE-2719)1810003
|k AG Prüß
|l Autoimmune Enzephalopathies
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1810003
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21